MedTrace Logo

Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

NCT01383005 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2013-05-06

Study results available
· View outcomes & findings →

Summary

Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).

Since once-a-day dosing is actually a driver for human immunodeficiency virus (HIV)-infected patients to request a specific antiretroviral, the aim of this study is to assess both patient's perception of and adherence to Kaletra once-a-day, as well as with which factors they are related.

Conditions

  • Human Immunodeficiency Virus Infection

Sponsors & Collaborators

  • Triaca Magna, SA

    collaborator UNKNOWN

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Angel Burgos, PhD · AbbVie S.L.U.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01383005 on ClinicalTrials.gov